Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2493MR)

This product GTTS-WQ2493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10961MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4957MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ7405MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ4026MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ13666MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ1611MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ15742MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ15787MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW